L70.3 Insurance Policy Changes

ICD-10 L70.3 is officially defined as "Acne tropica." code L70.3 is referenced in 4 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code L70.3 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Free Testosterone Testing
Serum free testosterone (CPT 84402) is medically necessary to distinguish a sex hormone-binding globulin (SHBG) abnormality from hypogonadism in obese males with symptoms of hypogonadism when total testosterone is low, to diagnose hyperandrogenism in symptomatic females, and in patients with a medical diagnosis that may increase or decrease SHBG levels. It is not medically necessary to diagnose testosterone deficiency in non-obese males with symptoms of hypogonadism, or when performed for screening of asymptomatic patients. Free testosterone should be performed by equilibrium dialysis, and free testosterone measured by an analog method should never be ordered.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Isotretinoin Products
Prior authorization is required for isotretinoin products (Absorica, Absorica LD, Accutane, Amnesteem, Claravis and Zenatane) under this BCBSMS policy. Absorica and Absorica LD are currently not covered on any BCBSMS formulary, and the use of samples does not count as current or stable therapy. The most recent update, dated 05/26/2026, added Accutane to the list of drugs, removed an ICD-9 diagnosis code from the code reference, and left the policy statements unchanged.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.109a, Procedures for the Treatment of Acne
This is a reissue of Independence Blue Cross Medicare Advantage Policy MA11.109a confirming the Company's continuing position that laser therapy, electrosurgery, cryosurgery, and chemosurgery for treatment of active acne are NOT covered (experimental/investigational), and services for acne scarring are NOT covered (cosmetic). No substantive policy changes have been made; this is a routine review and reissue.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.109a, Procedures for the Treatment of Acne
Independence Blue Cross has reissued MA11.109a to reaffirm that laser therapy, electrosurgery, cryosurgery, and chemosurgery (chemical peels) for treating active acne vulgaris remain non-covered as experimental/investigational procedures under Medicare Advantage plans. These same procedures for acne scarring remain non-covered as cosmetic services. This is a reaffirmation of the Company's continuing position with no substantive changes to coverage criteria.

Watch L70.3

Get one email when a payer policy names L70.3, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code L70.3?

There are 4 tracked policy changes affecting code L70.3, including updates from Blue Cross & Blue Shield of Mississippi, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code L70.3?

Payers that have issued tracked updates for code L70.3 include: Blue Cross & Blue Shield of Mississippi, Independence Blue Cross.

How do I get notified when code L70.3 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code L70.3. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code L70.3?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Free Testosterone Testing

Isotretinoin Products

MA11.109a, Procedures for the Treatment of Acne

MA11.109a, Procedures for the Treatment of Acne

What insurance policy changes affect code L70.3?

Which payers have updated policy for code L70.3?

How do I get notified when code L70.3 policy changes?

Why do payers change policies for code L70.3?